You are here: Industry Insights > head and neck cancer

News List

Hoarse Voice? There's Many Reasons for Rasping, Experts Say drugs
May 24, 2021
Hoarseness is common and there are many causes, an expert says.
AZ’s Imfinzi fails to improve overall survival in head and neck cancer again pharmatimes
February 09, 2021
AstraZeneca’s Imfinzi has failed to improved overall survival (OS) in patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) for the second time.
Junshi, Merck Collaborate on Head, Neck Cancer Treatment in China americanpharmaceuticalreview
June 11, 2020
Junshi Biosciences and Merck announced their collaboration on a clinical trial program designed to investigate the efficacy and safety of anti-PD-1 mAb toripalimab (TUOYI®) in combination with Cetuximab (Erbitux®) ...
Merck, Pfizer terminate Bavencio head and neck cancer trial pharmatimes
March 17, 2020
Merck KGaA and Pfizer have decided to stop their Phase III JAVELIN study testing Bavencio (avelumab) as a potential treatment for certain patients with advanced head and neck cancer.
NICE requests more data on Keytruda for head and neck cancer treatment europeanpharmaceuticalreview
January 17, 2020
NICE has asked for more information on Keytruda (pembrolizumab) for untreated metastatic or unresectable recurrent squamous cell head and neck cancer due to uncertainty over clinical trial evidence.
QBiotics Announces First Patient Dosed in its Phase I/II Clinical Trial of Tigilanol Tiglate for Head and Neck Cancer En-CPhI.CN
December 03, 2019
QBiotics Group Limited (QGL), a life sciences company developing novel anticancer and wound healing pharmaceuticals ...
Immunotherapy extends the life of head and neck cancer patients pharmatimes
December 04, 2018
A new immunotherapy can greatly extend the lives of a proportion of people with advanced head and neck cancer, with some living for three years or more, reports a major new clinical trial.
Head and neck cancer market fertile for investment europeanpharmaceuticalreview
March 09, 2017
A substantial number of first-in-class products in the head and neck cancer pipeline will reach the market over the coming decade, which could potentially transform the clinical and commercial landscape, according to business intelligence firm GBI Researc